These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 16456093

  • 21. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy.
    Vikramadithyan RK, Hirata K, Yagyu H, Hu Y, Augustus A, Homma S, Goldberg IJ.
    J Pharmacol Exp Ther; 2005 May; 313(2):586-93. PubMed ID: 15671204
    [Abstract] [Full Text] [Related]

  • 22. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
    Ide T, Tsunoda M, Mochizuki T, Murakami K.
    Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
    [Abstract] [Full Text] [Related]

  • 23. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K.
    Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
    [Abstract] [Full Text] [Related]

  • 24. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
    Lanne B, Dahllöf B, Lindahl C, Ebefors K, Kanmert I, von Bahr H, Miliotis T, Nyström AC, Arnerup G, Paulsons I, Kerb S, Oakes N.
    J Proteome Res; 2006 Aug; 5(8):1850-9. PubMed ID: 16889406
    [Abstract] [Full Text] [Related]

  • 25. Quantitative image analysis in adipose tissue using an automated image analysis system: differential effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist on white and brown adipose tissue morphology in AKR obese and db/db diabetic mice.
    Okamoto Y, Higashiyama H, Inoue H, Kanematsu M, Kinoshita M, Asano S.
    Pathol Int; 2007 Jun; 57(6):369-77. PubMed ID: 17539968
    [Abstract] [Full Text] [Related]

  • 26. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC.
    Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
    [Abstract] [Full Text] [Related]

  • 27. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
    Sharma S, Sowjanya A, Kumari M, Suryaprakash R, Cynthia G, Suresh J, Chakrabarti R.
    Life Sci; 2006 Dec 23; 80(3):235-44. PubMed ID: 17014868
    [Abstract] [Full Text] [Related]

  • 28. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF.
    Circulation; 2007 Sep 18; 116(12):1404-12. PubMed ID: 17724261
    [Abstract] [Full Text] [Related]

  • 29. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A, Godio C, Laghezza A, Mitro N, Fracchiolla G, Tortorella V, Lavecchia A, Novellino E, Fruchart JC, Staels B, Crestani M, Loiodice F.
    J Med Chem; 2005 Aug 25; 48(17):5509-19. PubMed ID: 16107150
    [Abstract] [Full Text] [Related]

  • 30. A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism.
    Xu C, Wang LL, Liu HY, Ruan CM, Zhou XB, Cao YL, Li S.
    Biotechnol Lett; 2006 Jun 25; 28(12):863-8. PubMed ID: 16786270
    [Abstract] [Full Text] [Related]

  • 31. Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin.
    Oana F, Takeda H, Hayakawa K, Matsuzawa A, Akahane S, Isaji M, Akahane M.
    Metabolism; 2005 Aug 25; 54(8):995-1001. PubMed ID: 16092047
    [Abstract] [Full Text] [Related]

  • 32. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
    Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB.
    J Med Chem; 2005 Apr 07; 48(7):2262-5. PubMed ID: 15801817
    [Abstract] [Full Text] [Related]

  • 33. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
    Verreth W, De Keyzer D, Davey PC, Geeraert B, Mertens A, Herregods MC, Smith G, Desjardins F, Balligand JL, Holvoet P.
    Br J Pharmacol; 2007 Jun 07; 151(3):347-55. PubMed ID: 17384667
    [Abstract] [Full Text] [Related]

  • 34. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O, Syha Y, Zettl H, Kock M, Bock A, Schubert-Zsilavecz M.
    Arch Pharm (Weinheim); 2008 Mar 07; 341(3):191-5. PubMed ID: 18275039
    [Abstract] [Full Text] [Related]

  • 35. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
    Tsunoda M, Kobayashi N, Ide T, Utsumi M, Nagasawa M, Murakami K.
    Am J Physiol Endocrinol Metab; 2008 May 07; 294(5):E833-40. PubMed ID: 18212024
    [Abstract] [Full Text] [Related]

  • 36. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG, Kim NJ, Koo BW, Lee KO, Moon SH, Shin DH, Jung JW, Paek SM, Chang DJ, Li F, Kang HJ, Le TV, Chae YN, Shin CY, Kim MK, Lim JI, Ryu JS, Park HJ.
    J Med Chem; 2008 Oct 23; 51(20):6318-33. PubMed ID: 18826205
    [Abstract] [Full Text] [Related]

  • 37. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue.
    Guri AJ, Hontecillas R, Ferrer G, Casagran O, Wankhade U, Noble AM, Eizirik DL, Ortis F, Cnop M, Liu D, Si H, Bassaganya-Riera J.
    J Nutr Biochem; 2008 Apr 23; 19(4):216-28. PubMed ID: 17618105
    [Abstract] [Full Text] [Related]

  • 38. The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
    Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q, Lu XP, Xie MZ, Shen ZF.
    Br J Pharmacol; 2006 Jul 23; 148(5):610-8. PubMed ID: 16751799
    [Abstract] [Full Text] [Related]

  • 39. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat.
    Steinmetz M, Quentin T, Poppe A, Paul T, Jux C.
    Basic Res Cardiol; 2005 May 23; 100(3):263-9. PubMed ID: 15754086
    [Abstract] [Full Text] [Related]

  • 40. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S.
    J Pharmacol Exp Ther; 2006 Aug 23; 318(2):863-71. PubMed ID: 16682454
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.